May 08, 2024 4:01pm EDT LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 01, 2024 4:01pm EDT LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
Apr 03, 2024 7:00am EDT LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Apr 02, 2024 4:01pm EDT LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
Mar 21, 2024 4:30pm EDT LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
Mar 07, 2023 8:00am EST LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies
Oct 18, 2022 8:00am EDT LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia
Apr 13, 2022 7:00am EDT LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics